Roche's is embarking upon a brave pricing strategy for its new multiple sclerosis drug Ocrevus (ocrelizumab) now that it has finally been licensed by the US FDA, following a slight technical hitch over manufacturing. The drug has been approved to treat both relapsing-remitting MS (RRMS) patients and the underserved primary progressive MS (PPMS) population and has been priced competitively.
The wholesale acquisition cost (WAC) has been set at $65,000, a "25% discount to [Pfizer Inc./Merck KGAA's] Rebif [interferon...